IRF9 and triple-negative breast carcinoma: However, IRF9 has been shown to confer chemoresistance in breast cancer, and suggested as a prognostic marker for chemotherapy and overall survival in triple-negative breast cancer (TNBC), in which high IRF9 levels are associated with a better outcome [39,40].